2024
Global patterns of rebound to normal RSV dynamics following COVID-19 suppression
Thindwa D, Li K, Cooper-Wootton D, Zheng Z, Pitzer V, Weinberger D. Global patterns of rebound to normal RSV dynamics following COVID-19 suppression. BMC Infectious Diseases 2024, 24: 635. PMID: 38918718, PMCID: PMC11201371, DOI: 10.1186/s12879-024-09509-4.Peer-Reviewed Original Research
2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2022
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variant